Novozymes to still run on bioethanol
Upon a standout financial report on the company's bioenergy business, CFO says there are still fine growth opportunities in the industry.
Novozymes is back on track. After the coronavirus pandemic put the Danish enzyme producer's bioenergy division in the lowest possible gear due to the crucial US market going on lockdown, drastically reducing car mileage, the reopening has entailed a corresponding positive change. More precisely, improved sales by more than 50 percent.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bioenergy sales grow markedly at Novozymes
For subscribers
Novozymes' US growth outlook dwindles
For subscribers
.jpg&w=384&q=75){kind=logo}
